MX2020009478A - Compuestos y sus usos para tratar tumores en un paciente. - Google Patents
Compuestos y sus usos para tratar tumores en un paciente.Info
- Publication number
- MX2020009478A MX2020009478A MX2020009478A MX2020009478A MX2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A MX 2020009478 A MX2020009478 A MX 2020009478A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- icd
- subject
- treat tumors
- relates
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000037449 immunogenic cell death Effects 0.000 abstract 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con compuestos que pueden usarse para inducir la muerte celular inmunogénica (ICD). En algunos casos, dos o más compuestos se combinan para inducir la ICD. La invención también se relaciona con la combinación de los compuestos que inducen la ICD con un agente que estimula el sistema inmunológico, tal como un inhibidor del punto de control inmunológico, en particular, para tratar cánceres o inhibir el crecimiento tumoral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161849 | 2018-03-14 | ||
| PCT/EP2019/056287 WO2019175243A1 (en) | 2018-03-14 | 2019-03-13 | Compounds and uses thereof to treat tumors in a subject |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009478A true MX2020009478A (es) | 2020-10-22 |
Family
ID=61655700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009478A MX2020009478A (es) | 2018-03-14 | 2019-03-13 | Compuestos y sus usos para tratar tumores en un paciente. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210353614A1 (es) |
| EP (1) | EP3765019A1 (es) |
| JP (1) | JP2021517145A (es) |
| KR (1) | KR20200131270A (es) |
| CN (1) | CN111867589A (es) |
| AU (1) | AU2019233596A1 (es) |
| CA (1) | CA3093499A1 (es) |
| IL (1) | IL277158A (es) |
| MX (1) | MX2020009478A (es) |
| RU (1) | RU2020133020A (es) |
| WO (1) | WO2019175243A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230069147A (ko) * | 2020-09-18 | 2023-05-18 | 메르크 파텐트 게엠베하 | 약학 제제 |
| US20230372319A1 (en) * | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
| CN119855608A (zh) * | 2022-09-16 | 2025-04-18 | 应世生物科技(南京)有限公司 | Fak抑制剂及拓扑异构酶抑制剂的药物组合及用途 |
| WO2024189299A1 (en) * | 2023-03-10 | 2024-09-19 | University Of Southampton | Inhibitors for treating solid tumours |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| AU2011339929B2 (en) * | 2010-12-06 | 2017-05-11 | Tom C. Tsang | Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| PL3277681T3 (pl) | 2015-04-02 | 2019-10-31 | Merck Patent Gmbh | Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm |
| JP2018527377A (ja) * | 2015-09-16 | 2018-09-20 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 癌の処置におけるトポイソメラーゼ−ｉ阻害剤と免疫療法との組み合わせ |
| PE20181895A1 (es) * | 2016-03-21 | 2018-12-11 | Astrazeneca Ab | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer |
| EP3664778B1 (en) * | 2017-08-11 | 2022-05-25 | Merck Patent GmbH | Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile |
-
2019
- 2019-03-13 EP EP19712706.1A patent/EP3765019A1/en not_active Withdrawn
- 2019-03-13 WO PCT/EP2019/056287 patent/WO2019175243A1/en not_active Ceased
- 2019-03-13 US US16/980,058 patent/US20210353614A1/en not_active Abandoned
- 2019-03-13 AU AU2019233596A patent/AU2019233596A1/en not_active Abandoned
- 2019-03-13 RU RU2020133020A patent/RU2020133020A/ru unknown
- 2019-03-13 MX MX2020009478A patent/MX2020009478A/es unknown
- 2019-03-13 CN CN201980018987.0A patent/CN111867589A/zh active Pending
- 2019-03-13 CA CA3093499A patent/CA3093499A1/en active Pending
- 2019-03-13 KR KR1020207028629A patent/KR20200131270A/ko not_active Withdrawn
- 2019-03-13 JP JP2020547353A patent/JP2021517145A/ja active Pending
-
2020
- 2020-09-06 IL IL277158A patent/IL277158A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210353614A1 (en) | 2021-11-18 |
| IL277158A (en) | 2020-10-29 |
| RU2020133020A (ru) | 2022-04-14 |
| WO2019175243A1 (en) | 2019-09-19 |
| JP2021517145A (ja) | 2021-07-15 |
| KR20200131270A (ko) | 2020-11-23 |
| AU2019233596A1 (en) | 2020-10-08 |
| CN111867589A (zh) | 2020-10-30 |
| CA3093499A1 (en) | 2019-09-19 |
| EP3765019A1 (en) | 2021-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| MY185579A (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| PH12021551047A1 (en) | Anti-ptk7 immune cell cancer therapy | |
| ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| MX2021005398A (es) | Terapia del cancer con celulas inmunitarias anti-cd33. | |
| ZA202405748B (en) | Universal abt compounds and uses thereof | |
| PH12019502132A1 (en) | Combination therapy for the treatment or prevention of tumours | |
| MY198289A (en) | Pharmaceutical Composition for use in a Method of Removing Immune Suppression in a Tumor Microenvironment or Stimulating an Immune System Against Cancer Cells | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MY182232A (en) | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations | |
| WO2017059319A3 (en) | Combination therapy of bromodomain inhibitors and checkpoint blockade | |
| WO2018094190A3 (en) | Gut microbiota and treatment of cancer | |
| MY192703A (en) | Compositions containing tucaresol or its analogs | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| AU2015279834A8 (en) | Use of peptides that block metadherin-SND1 interaction as treatment for cancer | |
| MX2023011105A (es) | Virus oncoliticos optimizados y usos de los mismos. | |
| NZ712691A (en) | C. novyi for the treatment of solid tumors in humans | |
| MX394425B (es) | Terapia de combinación con bromodominio e inhibidor de proteína extra terminal. | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| PH12022551078A1 (en) | Combination therapy to treat brain cancer | |
| MX2022002699A (es) | Lurbinectedina en el tratamiento del mesotelioma maligno. | |
| EA202192964A1 (ru) | Комбинированная терапия |